Peak Group (600668.SH) subsidiary Peak Pharmaceuticals passes drug GMP compliance inspection.

Intelligence financial news app, Peak Group (600668.SH) announced that recently, its wholly-owned subsidiary Zhejiang Peak Pharmaceutical Co., Ltd. (referred to as "Peak Pharmaceutical") received the GMP compliance inspection results announcement (Zhe 2025 No. 0254) from the Zhejiang Provincial Drug Administration's website. This time, the production line of tamsulosin raw material drug of Peak Pharmaceutical passed the GMP compliance inspection, which has the ability to supply the raw material drug of the drug, ensuring the production of tamsulosin eye drops, further enriching the company's product line.